function and regulated expression of membrane transporters which influence absor-
ption, distribution, and elimination pathways of pharmaceuticals and biologicals.
The comparative study ofP-gp and other transporters with particular emphasis on
species- and tissue-specific distribution is likely to lead to (1) a reduction in drug–
drug interactions, (2) the potential to optimise drug safety and efficacy profiles, and
(3) breed-specific dosing schedules based on differences in genetic make-up (see
chapter, “Pharmacogenomics in Domestic Animal Species”).
AcknowledgementWe thank George Retseck Illustration, Pennsylvania, USA, for the artwork.
Emilie Oudot is funded by the Irish Council for Science Engineering and Technology and Pfizer
Animal Health (UK).
References
Alcon V, Baca-Estrada M, Vega-Lopez M, Willson P, Babiuk LA, Kumar P, Hecker R, Foldvari M
(2005) Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in
biphasic lipid vesicles in pigs. AAPS J 7:E566–E571
Alvarez AI, Merino G, Molina AJ, Pulido MM, McKellar QA, Prieto JG (2006) Role of ABC
transporters in veterinary drug research and parasite resistance. Curr Drug Deliv 3:199–206
Aragon CL, Read MR, Gaynor JS, Barnhart MD, Wilson D, Papich MG (2009) Pharmacokinetics
of an immediate and extended release oral morphine formulation utilizing the spheroidal oral
drug absorption system in dogs. J Vet Pharmacol Ther 32:129–136
Arther RG, Cunningham J, Dorn H, Everett R, Herr LG, Hopkins T (1997) Efficacy of imidacloprid
for removal and control of fleas (Ctenocephalides felis) on dogs. Am J Vet Res 58:848–850
Aslan V, Maden M, Erganis O, Birdane FM, Corlu M (2002) Clinical efficacy of florfenicol in the
treatment of calf respiratory tract infections. Vet Q 24:35–39
Baeyens V, Percicot C, Zignani M, Deshpande AA, Kaltsatos V, Gurny R (1997) Ocular drug
delivery in veterinary medicine. Adv Drug Deliv Rev 28:335–361
Baeyens V, Felt-Baeyens O, Rougier S, Pheulpin S, Boisrame ́B, Gurny R (2002) Clinical
evaluation of bioadhesive ophthalmic drug inserts (BODI) for the treatment of external ocular
infections in dogs. J Control Release 85:163–168
Ball AM, Smith KM (2008) Optimizing transdermal drug therapy. Am J Health Syst Pharm
65:1337–1346
Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Lo ̈scher W (2007) Differences in the
transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and
mouse P-glycoprotein. Neuropharmacology 52:333–346
Barbet JL, Snook T, Gay JM, Mealey K (2009) ABCB1–1 Delta (MDR1–1 Delta) genotype is
associated with adverse reactions in dogs treated with milbemycin oxime for generalized
demodicosis. Vet Dermatol 20:111–114
Barbu E, Sarvaiya I, Green KL, Nevell TG, Tsibouklis J (2005) Vinylpyrrolidone-co-(meth)
acrylic acid inserts for ocular drug delivery: synthesis and evaluation. J Biomed Mater Res
A 74:598–606
Beal MW, Poppenga RH, Birdsall WJ, Hughes D (1999) Respiratory failure attributable to
moxidectin intoxication in a dog. J Am Vet Med Assoc 215:1813–1817
Bernstein G (2008) Delivery of insulin to the buccal mucosa utilizing the RapidMist 1 system.
Exp Opin Drug Deliv 5:1047–1055
Bidwell LA, Wilson DV, Caron JP (2007) Lack of systemic absorption of lidocaine from 5%
patches placed on horses. Vet Anaesth Analg 34:443–446
104 D.J. Brayden et al.